Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21930099 | 0.81 | HDAC6 (0.33) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL6959863 | 0.78 | L3MBTL1 (0.32) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL956549 | 0.77 | ALDH1A1 (0.42) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL2622073 | 0.77 | HDAC6 (0.38) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL2754735 | 0.76 | HDAC6 (0.37) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL17162509 | 0.76 | HDAC6 (0.37) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL25036963 | 0.74 | HDAC6 (0.36) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL1810981 | 0.74 | HDAC6 (0.36) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL22604686 | 0.74 | HDAC6 (0.36) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL6714665 | 0.73 | HDAC6 (0.35) | HDAC6HDAC1HDAC2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | HDAC6 1171/4885HDAC1 1155/4885HDAC2 430/4885 |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | RIPK2, RIPK1, RIPK4 | HDAC6 1171/4885HDAC1 1155/4885HDAC2 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.